Idelalisib with Atogepant Interaction Details
Brand Names Associated with Idelalisib
- Idelalisib
- Zydelig®
Brand Names Associated with Atogepant
- Atogepant
- Qulipta®
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Mar 04, 2024
Interaction Effect
Increased atogepant exposure
Interaction Summary
Coadministration of atogepant (CYP3A4 substrate) with a strong CYP3A4 inhibitor may significantly increase atogepant exposure. In a pharmacokinetic study, coadministration of atogepant with itraconazole (strong CYP3A4 inhibitor) increased atogepant AUC by 5.5-fold and Cmax by 2.15-fold. Population modeling suggests concomitant use of a weak or moderate CYP3A4 inhibitor will not lead to clinically meaningful changes in atogepant exposure. For episodic migraine, the recommended dosage of atogepant with strong CYP3A4 inhibitors is 10 mg orally once daily. For chronic migraine, avoid concomitant use of strong CYP3A4 inhibitors with atogepant[1].
Severity
Major
Onset
Unspecified
Evidence
Probable
How To Manage Interaction
Coadministration of atogepant with a strong CYP3A4 inhibitor may significantly increase atogepant exposure. For episodic migraine, the recommended dosage of atogepant with strong CYP3A4 inhibitors is 10 mg orally once daily. For chronic migraine, avoid concomitant use of strong CYP3A4 inhibitors with atogepant[1].
Mechanism Of Interaction
Inhibition of CYP3A4-mediated metabolism of atogepant
Literature Reports
A) In a pharmacokinetic study, coadministration of atogepant with itraconazole (strong CYP3A4 inhibitor) increased atogepant AUC by 5.5-fold and Cmax by 2.15-fold in healthy subjects [1].
B) Population pharmacokinetic modeling predicts coadministration of atogepant with a moderate or weak CYP3A4 inhibitor will increase atogepant AUC by 1.7- and 1.1-fold, respectively. This suggested change in atogepant exposure is not expected to be clinically relevant [1].
References
1 ) Product Information: QULIPTA(R) oral tablets, atogepant oral tablets. AbbVie Inc (per FDA), North Chicago, IL, 2023.
Idelalisib Overview
-
Idelalisib is used along with another medication rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) in people whose cancer came back after receiving other cancer treatments. It is also used to treat certain types of follicular lymphoma (FL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL:a type of cancer that begins in the white blood cells) in people whose cancer came back after being treated with at least 2 other cancer treatments. Idelalisib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Atogepant Overview
-
Atogepant is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Atogepant is in a class of medications called calcitonin gene-related peptide receptor antagonists. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.